Study confirms: Multigene test is a useful decision making tool in breast cancer treatment

December 7, 2018, Technical University Munich

Multigene tests have been used in breast cancer treatment to assess the risk of metastasis for several years. A team at the Breast Cancer Center at the Technical University of Munich's (TUM) Klinikum rechts der Isar has now presented results based on data collected in its routine clinical work. These results show that the multigene test used at the university hospital is indeed helpful in making more targeted use of chemotherapy treatments and thus improves prognosis of breast cancer patients.

Since November 2011, the Gynecological Clinic at Klinikum rechts der Isar has used a multigene test for patients with early hormone receptor-positive, HER2-negative breast . Using tissue samples and other clinical indicators, the test helps to determine a patient's risk of metastasis. "Based on the test results, which combine molecularbiological properties of the tumor along with the individual factors of tumor size and the presence of cancer in lymph nodes, doctors decide whether is recommended in addition to the surgical removal of the tumor followed by anti-hormone treatment," explains Prof. Marion Kiechle, the Director of the Gynecological Clinic. "In case of a low metastasis risk, chemotherapy may place an unnecessary burden on the patient. But in case of a high risk, it may prevent tumors from relapsing later."

At the San Antonio Breast Cancer Symposium in the USA, one of the world's most important congresses in that field, Dr. Johannes Ettl, Head Physician of the Gyneco-Oncological Outpatient Clinic, Technical University of Munich, Germany has now presented the results of an independent study not commissioned by a test manufacturer of the test used at the Breast Center.

373 patients tested

For the study, Dr. Ettl and his team tracked 373 cancer patients from the start of initial and the related multigene test. The test indicated a low risk for 238 patients (63.8%) and a high risk for 135 (36.2%). After a median follow up of 3.5 years, the risk for disease recurrence was twice as high in the high-risk group as in the low-risk group. Similarly, high risk patients were at five-fold increased risk of developing metastases in other organs. The low-risk and high-risk patients who received chemotherapy in addition to anti-hormone tablets had three-year disease free survival rates of 96.6% and 96.3%, respectively. By contrast, for high-risk who did not receive chemotherapy despite the doctors' recommendation based on the , the rate was only 91.5%.

"Our health care study has delivered the first data from routine clinical practice indicating that the does, in fact, provide useful input when deciding on chemotherapy," says Prof. Kiechle. "Gene signature tests are important tools that help us to make more targeted use of chemotherapy treatments, both by limiting unnecessarily stressful treatments and avoiding the potentially serious consequences of rejecting chemotherapy in case of high metastasis risks."

Explore further: Delaying adjuvant chemo associated with worse outcomes for patients with triple-negative breast cancer

More information: First prospective outcome data for the clinico-molecular test Endopredict in hormone receptor positive, HER2-negative early breast cancer in clinical routine , www.abstracts2view.com/sabcs18 … =SABCS18L_1275&terms

Related Stories

Delaying adjuvant chemo associated with worse outcomes for patients with triple-negative breast cancer

December 5, 2018
Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started ...

Circulating tumor cell count could help choose treatment for metastatic breast cancer patients

December 6, 2018
Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according ...

Some patients with metastatic triple negative breast cancer live longer with immunotherapy

October 22, 2018
Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

Biomarker tests in breast cancer: New study data indicate advantage for certain patients

September 6, 2018
The German Institute for Quality and Efficiency in Health Care (IQWiG) reinvestigated the benefit of biomarker tests to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, ...

Landmark study finds more breast cancer patients can safely forgo chemotherapy

June 3, 2018
A 21-gene test performed on tumors could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study published in the New England Journal of Medicine.

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

June 4, 2018
New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study ...

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.